ArticleNature communications2024
Spatial and temporal transmission dynamics of respiratory syncytial virus in New Zealand before and after the COVID-19 pandemic.
Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Mapping Sub-National Respiratory Virus Circulation in Cambodia Using Metatranscriptomic Sequencing: A Multi-Center Hospital-Based Surveillance Study.Influenza and other respiratory viruses · 2026Article
- Genomic Diversity of Human Respiratory Syncytial Virus (HRSV) Type A in a Pediatric Cohort in the United States After the Onset of the COVID-19 Pandemic.Microorganisms · 2026Article
- Evolutionary dynamics of Respiratory Syncytial Virus in pre-pandemic, pandemic, and post-pandemic periods in Houston, Texas, USA.bioRxiv : the preprint server for biology · 2026Article
- Epidemiological characteristics of hospitalized pediatric patients with acute respiratory tract infection during and after the COVID-19 period in Ningbo, China: a retrospective single-center study.BMC infectious diseases · 2026Article
- Observational
- Genomic Surveillance of Respiratory Syncytial Virus in Sydney Reveals Rebound in Postpandemic Viral Diversity.Open forum infectious diseases · 2026Article
- Reconstructing severe acute respiratory infection dynamics from ICD-10 hospital discharge data: a 10-year analysis of 11.2 million discharges in Ecuador, 2014-2023.Frontiers in public health · 2026Article
- Shifts in acute respiratory pathogen epidemiology: an 8-year surveillance study in Hangzhou, China (2018-2025).Frontiers in public health · 2026Article
- Genomic Insights Into Respiratory Syncytial Virus Circulation Patterns and Neutralization by Anti-F Monoclonal Antibodies in Panama (2018-2024).Influenza and other respiratory viruses · 2025Article
- Changes in Respiratory Viruses' Activity in Children During the COVID-19 Pandemic: A Systematic Review.Journal of clinical medicine · 2025Review
Corrections and comments
- Update of
Authors and funding
29 authors.
Funding
Abstract
Human respiratory syncytial virus (RSV) is a major cause of acute respiratory infection. In 2020, RSV was eliminated from New Zealand due to non-pharmaceutical interventions (NPI) used to control the spread of SARS-CoV-2. However, in 2021, following a brief quarantine-free travel agreement with Australia, there was a large-scale nationwide outbreak of RSV that led to reported cases more than five-times higher than typical seasonal patterns. We generated 1470 viral genomes of both RSV-A and RSV-B sampled between 2015-2022 from across New Zealand. Using a phylodynamics approach, we used these data to better understand RSV transmission patterns in New Zealand prior to 2020, and how RSV became re-established in the community following the relaxation of COVID-19 restrictions. We found that in 2021, there was a large epidemic of RSV due to an increase in importations, leading to several large genomic clusters of both RSV-A ON1 and RSV-B BA9 genotypes. However, while a number of viral importations were detected, there was also a major reduction in RSV genetic diversity compared to pre-pandemic years. These data reveal the impact of NPI used during the COVID-19 pandemic on other respiratory infections and highlight the important insights that can be gained from viral genomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.